{"organizations": [], "uuid": "e79ebd101b62ad90e5ca94a860a011d13e07ef36", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-lipocine-says-fdas-brudac-voted-6/brief-lipocine-says-fdas-brudac-voted-6-in-favor-13-against-benefit-risk-profile-of-tlando-idUSFWN1P50QW", "country": "US", "domain_rank": 408, "title": "BRIEF-Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-10T23:33:00.000+02:00", "replies_count": 0, "uuid": "e79ebd101b62ad90e5ca94a860a011d13e07ef36"}, "author": "", "url": "https://www.reuters.com/article/brief-lipocine-says-fdas-brudac-voted-6/brief-lipocine-says-fdas-brudac-voted-6-in-favor-13-against-benefit-risk-profile-of-tlando-idUSFWN1P50QW", "ord_in_thread": 0, "title": "BRIEF-Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "brudac", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "against benefit/risk profile of tlando reuters", "sentiment": "none"}, {"name": "lipocine inc", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 10, 2018 / 9:34 PM / Updated 9 minutes ago BRIEF-Lipocine Says FDA's BRUDAC Voted 6 In Favor & 13 Against Benefit/Risk Profile Of Tlando Reuters Staff 1 Min Read \nJan 10 (Reuters) - Lipocine Inc: \n* LIPOCINE - FDA‘S BRUDAC VOTED 6 IN FAVOR & 13 AGAINST BENEFIT/RISK PROFILE OF CO‘S ORAL TESTOSTERONE PRODUCT CANDIDATE FOR TRT IN ADULT MALES, TLANDO \n* LIPOCINE INC SAYS ‍FDA DECISION ON TLANDO NDA IS ANTICIPATED BY ASSIGNED PDUFA GOAL DATE OF MAY 8, 2018 - SEC FILING ​ \n* LIPOCINE INC - CONTINUE TO BELIEVE EFFICACY AND SAFETY RESULTS FROM CLINICAL STUDIES WITH TLANDO CONSISTENT WITH OTHER FDA APPROVED TRT PRODUCTS Source text: ( bit.ly/2mnVzkJ ) Further company coverage:", "external_links": [], "published": "2018-01-10T23:33:00.000+02:00", "crawled": "2018-01-10T23:50:33.020+02:00", "highlightTitle": ""}